RankingsLogo

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is a Humankind 100 company whose ranking is based on its Humankind Value, a proprietary metric that provides an estimate of the overall dollar amount a company creates for investors, consumers, employees, and society at large.

Bristol-Myers Squibb Company is a pharmaceutical company that researches and develops medicines. It has made advancements in treatments for cancer, blood disorders, diabetes, and heart disease, among others. It also promotes better global access to medicines and health education.

Ticker: BMY

Humankind Value: $249.0 B

Revenue: $43.6 B

Market Cap: $88.7 B

Badge100_2024
Positive and negative impacts of companies graphic.

(All values are in US Dollars, where M=Million, B=Billion, T=Trillion.)

Bristol-Myers Squibb Company operates in a manner that is a net positive for humanity, with much of its positive value coming from Pharmaceuticals ($127.1 B), Healthcare R&D ($112.2 B), and Economic Value ($8.4 B). Positive value from Pharmaceuticals and Healthcare R&D is linked to an estimate of 4,600,000 additional years lived by people worldwide. Downsides for this company are associated with Greenhouse Gases (-$2.8 B) and Air Pollution (-$356.7 M). The company’s direct business activities are responsible for its impacts on Pharmaceuticals, Healthcare R&D, Economic Value, Greenhouse Gases, and Air Pollution.

How the Humankind Value Methodology Drives the Rankings

We take a quantitative, data-driven approach to estimating the economic impact that companies have on investors, customers, employees, and society at large, rolling social responsibility into a single dollar value that we use to represent what a company is contributing to humanity. As far as we can tell, we're the first ones doing it this way.

LEARN MORE ABOUT OUR RESEARCH
How Methodology Drives the Rankings